IL154034A0 - Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals - Google Patents

Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals

Info

Publication number
IL154034A0
IL154034A0 IL15403401A IL15403401A IL154034A0 IL 154034 A0 IL154034 A0 IL 154034A0 IL 15403401 A IL15403401 A IL 15403401A IL 15403401 A IL15403401 A IL 15403401A IL 154034 A0 IL154034 A0 IL 154034A0
Authority
IL
Israel
Prior art keywords
azaindole
antiangiogenic
indole
medicaments
warm
Prior art date
Application number
IL15403401A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL154034A0 publication Critical patent/IL154034A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL15403401A 2000-08-09 2001-08-08 Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals IL154034A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402257 2000-08-09
PCT/GB2001/003561 WO2002012227A2 (fr) 2000-08-09 2001-08-08 Composes chimiques

Publications (1)

Publication Number Publication Date
IL154034A0 true IL154034A0 (en) 2003-07-31

Family

ID=8173808

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15403401A IL154034A0 (en) 2000-08-09 2001-08-08 Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals

Country Status (14)

Country Link
US (2) US20030207878A1 (fr)
EP (1) EP1311500A2 (fr)
JP (1) JP2004505965A (fr)
KR (1) KR20030029812A (fr)
CN (1) CN1245402C (fr)
AU (2) AU7993801A (fr)
BR (1) BR0113078A (fr)
CA (1) CA2416525A1 (fr)
IL (1) IL154034A0 (fr)
MX (1) MXPA03000874A (fr)
NO (1) NO20030628L (fr)
NZ (1) NZ523987A (fr)
WO (1) WO2002012227A2 (fr)
ZA (1) ZA200300489B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2262935C2 (ru) 1999-02-10 2005-10-27 Астразенека Аб Производные хиназолина в качестве ингибиторов ангиогенеза
NZ518028A (en) 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
JP2003525897A (ja) 2000-03-06 2003-09-02 アストラゼネカ アクチボラグ 治 療
IL151626A0 (en) * 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
PT1474420E (pt) 2002-02-01 2012-05-10 Astrazeneca Ab Compostos de quinazolina
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US6933386B2 (en) * 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004030635A2 (fr) * 2002-10-03 2004-04-15 Targegen, Inc. Agents vasculo-statiques et procedes d'utilisation de ceux-ci
PL215161B1 (pl) 2002-11-04 2013-10-31 Astrazeneca Ab Pochodne chinazoliny, sposób ich wytwarzania, kompozycje farmaceutyczne je zawierajace oraz ich zastosowanie
PT1625121E (pt) 2002-12-20 2010-03-11 Pfizer Prod Inc Derivados de piridina para o tratamento de crescimento celular anormal
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1601348A4 (fr) 2003-02-28 2008-12-10 Oxigene Inc Compositions et methodes presentant une activite therapeutique amelioree
US20040266688A1 (en) * 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
BRPI0511132A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina e composição farmacêutica compreendendo os mesmos
BRPI0510963A (pt) 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
CN104945311A (zh) 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
AU2010216263A1 (en) 2009-02-23 2011-07-14 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators
US8653079B2 (en) 2011-08-15 2014-02-18 Merck Sharp & Dohme Corp. Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators
CA2952857A1 (fr) * 2014-06-19 2015-12-23 Merial, Inc. Compositions parasiticides comprenant des derives d'indole, leurs procedes et leurs utilisations
WO2021254529A1 (fr) * 2020-07-14 2021-12-23 江苏先声药业有限公司 Composé bicyclique
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987332A (en) * 1975-10-09 1976-10-19 Varian Associates Gang tuner for multi-cavity klystron
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5237629A (en) * 1992-03-19 1993-08-17 The United States Of America As Represented By The United States Department Of Energy Digitally controlled distributed phase shifter
US5440270A (en) * 1992-07-14 1995-08-08 Linear Technology Corporation Linear-phase filter having high gain selectivity
SE9302453L (sv) * 1993-07-20 1994-10-17 Telia Ab Förfarande och anordning för synkronisering i digitalt transmissionssystem av typen OFDM
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JP3727406B2 (ja) * 1996-03-07 2005-12-14 株式会社日立国際電気 関数変換演算器
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ATE300521T1 (de) * 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
UA72881C2 (uk) * 1997-11-11 2005-05-16 Пфайзер Продактс Інк. Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
JPH11259454A (ja) * 1998-03-09 1999-09-24 Sharp Corp フーリエ変換装置
AU5620299A (en) * 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US20030162795A1 (en) * 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
KR200212866Y1 (ko) * 1998-12-26 2001-02-15 서평원 선왜곡 방식 전력증폭기용 능동 왜곡신호 발생회로
RU2331640C2 (ru) * 1999-05-21 2008-08-20 Бристол-Маерс Сквибб Ко. Пирролтриазиновые ингибиторы киназ
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
TR200402656T4 (tr) * 2000-06-06 2004-11-22 Pfizer Products Inc. Antikanser ajanları olarak faydalı tiyofen türevleri

Also Published As

Publication number Publication date
EP1311500A2 (fr) 2003-05-21
NO20030628L (no) 2003-04-08
US20060148819A1 (en) 2006-07-06
NO20030628D0 (no) 2003-02-07
MXPA03000874A (es) 2003-06-06
NZ523987A (en) 2004-10-29
BR0113078A (pt) 2003-07-01
AU2001279938B2 (en) 2007-01-25
JP2004505965A (ja) 2004-02-26
US20030207878A1 (en) 2003-11-06
CN1468230A (zh) 2004-01-14
CA2416525A1 (fr) 2002-02-14
ZA200300489B (en) 2004-04-19
AU7993801A (en) 2002-02-18
WO2002012227A3 (fr) 2002-08-01
CN1245402C (zh) 2006-03-15
WO2002012227A2 (fr) 2002-02-14
KR20030029812A (ko) 2003-04-16

Similar Documents

Publication Publication Date Title
IL154034A0 (en) Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals
IL149034A (en) Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeabiltiy reducing effect
IL155278A (en) Compressed Pyridine-4-On and Pyridine-4-On Derivatives
IL163022A (en) Quinazoline derivatives, processes for their manufacture, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments and as medicaments for the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals
IL162105A (en) INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS FOR INHIBITION OF FACTOR Xa
IL175487A (en) Pyrazole derivatives, a process for their preparation and use in the manufacture of drugs and drugs for inhibiting trk activity
IL164108A (en) Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
IL191486A0 (en) Piperidine derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for the treatment of tachykinis mediated conditions
HUP0204410A3 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
IL163894A (en) 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments
HUP0203052A3 (en) Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0200309A2 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them
HUP0401009A3 (en) 1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them
HUP0105079A3 (en) Indole derivatives and their use as mcp-1 antagonists, process for preparation of the compounds and medicaments containing them
HUP0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0202100A2 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same
IL167038A (en) Pyrazole derivatives, pharmaceutical compositions containing the same, use thereof in the manufacture of medicaments and intermediate for production thereof
HUP0303958A2 (hu) Heterociklusos oxi-, tioxi- és amino-benzazol-származékok, mint 5-hidroxitriptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HU0103063D0 (en) New 2h-pyridazin-3-one derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0402640A3 (en) Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions thereof
HUP0203140A3 (en) Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
HUP0400317A3 (en) Beta-carboline derivatives, process for their preparation, their use and pharmaceutical compositions containing them